Form 4: ProMIS Neurosciences CEO Receives Stock Option Grant

CEO Neil Warma was granted 160,000 stock options in ProMIS Neurosciences with an exercise price of $10.77.

Summary

• CEO Neil Warma received a grant of 160,000 stock options on May 20, 2026.
• The options have an exercise price of $10.77 per share.
• The options are set to expire on May 20, 2036.
• The grant vests ratably over a four-year period, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Vesting is subject to continued service, creating potential retention risk if the executive departs.

Future Outlook

The options vest ratably over four years, indicating a long-term retention strategy for the CEO.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to incentivize long-term clinical and commercial development milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive compensation in the biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised in the future.

Next Steps

• Vesting of options over the next four years.

Key Dates

Keywords

ProMIS Neurosciences, PMN, Neil Warma, Stock Options, Insider Transaction, Form 4